
P
LCλ
pA
P
HC knob
TM
pA
DHFR
Neo
Vector A
Leaky stop
P
LCκ
pA
P
HC hole
TM
pA
FolR
Hyg
Vector B

FIG 1



FIG 2A



FIG 2B



FIG 2C



FIG 2D



FIG 2E



FIG 3A



FIG 3B



FIG 3C



FIG 3D



FIG 4A



FIG 4B



FIG 4C



FIG 4D



FIG 4E



FIG 4F



FIG 4G



FIG 4H



FIG 4I



FIG 4J



FIG 4K



FIG 4L



FIG 4M



FIG 5


IFNγ protein whole blood (example)
IFNγ in pg/ml
40000
30000
20000
10000
0
0.01
0.1
1
10
100
1000
Compound in nM
mAb2
mAb1
bbmAb 1
Combo

FIG 6A


IFNγ protein whole blood (n=4)
% inhibition of IFN γ
100
80
60
40
20
0
mAb2
mAb1
bbmAb 1

FIG 6B


IFNγ protein PBMC (n= 9)
***
***
100
80
60
40
20
0
% inhibition
mAb2
mAb1
bbmAb1

FIG 7A


IFNγ gene expression PBMC (n= 9)
***
***
100
80
60
40
20
0
% inhibition
mAb2
mAb1
bbmAb 1

FIG 7B


IFNg mRNA expression levels
20000
16000
12000
8000
4000
0
unstimulated
LPS + IL-12 stimulated
stimulated + mAb2
stimulated + mAb1
stimulated + bbmAb1
donor1
donor2
donor3
donor4
donor5

FIG 8A


IL-26 mRNA expression levels
1200
1000
800
600
400
200
0
unstimulated
LPS + IL-12 stimulated
stimulated + mAb2
stimulated + mAb1
stimulated + bbmAb1
donor1
donor2
donor3
donor4
donor5

FIG 8B


IFNγ gene expression PBMC (n=5)
% inhibition
100
80
60
40
20
0
mAb2
mAb1
bbmAb1

FIG 9A


IL-26 gene expression PBMC (n=5)
% inhibition
100
80
60
40
20
0
mAb2
mAb1
bbmAb1

FIG 9B



FIG 10A



FIG 10B


1.00E-90
1.00E-84
1.00E-78
1.00E-72
1.00E-66
1.00E-60
1.00E-54
1.00E-48
1.00E-42
1.00E-36
1.00E-30
1.00E-24
1.00E-18
1.00E-12
1.00E-06
1.00E+00
IL1B DEG
IL18 DEG
IL1B IL18 DEG
IL1B DEG
IL18 DEG
IL1B IL18 DEG
6h
24h
Skin from cutaneous sarcoidosis lesions _vs_ skin from healthy patients
Skin from cutaneous sarcoidosis lesions _vs_ non-lesioned skin
Lacrimal glands from sarcoidosis patients _vs_ normal
Anterior orbit tissues from sarcoidosis patients _vs_ normal
Lungs - progressive fibrotic, pulmonary sarcoidosis_vs_ nodular, self-limiting pulmonary sarcoidosis

FIG 11